Successful erlotinib rechallenge in an EGFR‐mutant metastatic non‐small cell lung cancer patient with afatinib‐induced drug rash with eosinophilia and systemic symptoms: A case report
Abstract Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor (EGFR)‐mutant advanced‐stage non‐small cell lung cancer (NSCLC). However, TKIs can cause some severe adverse events, which are more prevalent within first‐generation EGFR‐TKI use than with seco...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14276 |
| Summary: | Abstract Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor (EGFR)‐mutant advanced‐stage non‐small cell lung cancer (NSCLC). However, TKIs can cause some severe adverse events, which are more prevalent within first‐generation EGFR‐TKI use than with second‐generation inhibitors. Herein, we report a case of a patient with advanced‐stage EGFR‐mutant NSCLC who developed drug reaction with eosinophilia and systemic symptoms (DRESS) after receiving treatment with afatinib. The patient was successfully rechallenged with erlotinib, without manifestations of skin rash in the following 6 months. Hence, erlotinib may be considered a potential substitute for other EGFR‐TKIs following DRESS occurrence. |
|---|---|
| ISSN: | 1759-7706 1759-7714 |